IPHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Innate Pharma SA (IPHA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, and there are no immediate positive catalysts or strong trading signals to justify an entry point. While analysts have a positive long-term outlook with a Buy rating and an $8 price target, the stock's current performance and lack of momentum suggest waiting for a better opportunity.
The stock is in a bearish trend with MACD below zero and negatively expanding, RSI in the neutral zone at 28.884, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 1.448, and resistance is at 1.747. The stock has an 80% chance to move -2.22% in the next week and 1.45% in the next month.
Analysts have a positive long-term outlook with three oncology assets expected to have catalysts in 2026, including monalizumab PACIFIC-9 topline data and IPH4502 Phase 1 data.
No significant hedge fund or insider trading trends, bearish technical indicators, and no recent news or congress trading data.
No financial data available for analysis.
BTIG assumed coverage with a Buy rating and an $8 price target, citing long-term oncology catalysts expected in 2026.
